Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium, Showing Promising Safety and Efficacy Results for Investigational OMNYPULSE Platform.
ByAinvest
Friday, Feb 6, 2026 7:08 pm ET1min read
JNJ--
Johnson & Johnson presented 12-month pilot-phase data from the OMNY-AF study, evaluating the OMNYPULSE Platform for symptomatic paroxysmal atrial fibrillation treatment. Initial results showed 100% acute procedural success, zero fluoroscopy in 56.7% of cases, and 90% primary effectiveness at 12 months. The OMNYPULSE Catheter and TRUPULSE Generator are designed for precise mapping, controlled energy delivery, and live feedback through the PF index on the CARTO 3 System. The OMNYPULSE Platform is not currently approved in any region.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet